AC Immune SA reported a net loss of CHF 19,190 thousand, or CHF 0.21 per share, for the first quarter ended March 31, 2025. The company's revenue for the period was CHF 1,000 thousand, which lagged analyst estimates.
Despite the financial results, AC Immune highlighted continued progress in its clinical development programs. Interim Phase 2 data on ACI-7104.056, its wholly owned alpha-synuclein active immunotherapy, demonstrated strong immunogenicity and a favorable safety profile in early Parkinson’s disease patients.
The company's partnered active immunotherapy programs, ACI-24.060 and ACI-35.030, also advanced well in their respective ongoing Phase 2 trials. AC Immune confirmed it is well financed into Q1 2027, excluding potential milestone payments, providing a stable financial runway.
Upcoming milestones for 2025 include pharmacodynamic and biomarker data on ACI-7104.056 and the potential initiation of Part 2 of the Phase 2 VacSYn trial. Additionally, the 12-month treatment timepoint for all Alzheimer’s disease cohorts of the Phase 2 ABATE trial of ACI-24.060 is expected by December 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.